News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Yamanouchi Pharmaceutical Co., Ltd. To License Gelpart Coronary Embolism Material To Nippon Kayaku Co., Ltd.


10/19/2005 5:12:39 PM

Tokyo (JCNN) - Yamanouchi Pharmaceutical has announced that it has concluded a licensing agreement with Nippon Kayaku for its proprietary product Gelpart. Under the terms of the agreement, Nippon Kayaku will receive the exclusive rights to Gelpart.

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES